Prostate cancer remains the most common cancer and the second commonest cause of cancer related death in Australian men.
This week Peter MacCallum Cancer Centre in Melbourne screened it's first patient as it commences the EVOLUTION trial
“We are on the verge of a complete transformation in prostate cancer treatment, giving men with the most aggressive and deadly forms of this disease a greater hope of survival. Prostate Cancer Foundation of Australia’s partnership with Australian and New Zealand Urogenital and Prostate Cancer Trial Group (ANZUP) has led much of this work over recent years, establishing Australian researchers as global leaders in this field and enabling more Australian men to live longer and better with prostate cancer. PCFA is proud to be part of this innovative new trial,” said PCFA CEO, Anne Savage.
The purpose of the EVOLUTION trial involving 100 patients is to see if combining two drugs ipilimumab and nivolumab, which activate the body's own immune system, with Lu-PSMA can further improve anti-cancer effects of Lu-PSMA. This new randomised phase 2 study will also determine the activity and safety of this combination in patients with mCRPC.
Professor Ian Davis, Chair of ANZUP made the following comment:
“EVOLUTION continues ANZUP’s mission of improving outcomes for people affected by prostate and other genitourinary cancers. This great collaboration brings together ANZUP, PCFA, our community of clinicians and researchers, and people directly affected by prostate cancer, to learn from what has gone before and to take new steps forward together. Clinical trials like EVOLUTION are the only way we make true progress in medical care,”
The full transcript of the article can be found at:
FYI: from the VA research information on Veterans 
Patterns of Cancer Progression of Metastatic Hormone-sensitive PCa in the ECOG3805 CHAARTED Trial
